← Eichor
Study identifier: NCT06957808 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia

Condition: Schizophrenia Disorders  ·  Sponsor: King's College London

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people. It is ranked the third most disabling illness worldwide. Six in seven patients do not recover from the illness in 6-12 months and continue to experience psychotic symptoms. Therefore, there is a strong unmet need for new evidence-based treatments to target the neurobiology underlying schizophrenia. There is increasing evidence to indicate that glutathione (GSH), the main brain antioxidant, is abnormal in schizophrenia and may provide a new treatment target. In this study, the investigators plan to determine whether Diroximel Fumarate (DRF) (currently a treatment for a brain disorder called multiple sclerosis) can increase GSH in the brain of patients with schizophrenia using a brain scan (MRI) and explore whether changes in GSH are related to other brain measures (measured with MRI and EEG- which measures electrical activity in the brain), blood markers of GSH, and symptoms. During this study 30 people with schizophrenia will be recruited. Participants will take the drug DRF for two weeks, a computer will then decide randomly whether each person will continue to take DRF or a placebo/dummy pill for another two weeks. During this part of the study neither the patients nor the researchers will know which type of drug the patient is taking. Brain GSH and the other …

This description comes directly from the study's public registry record.

Talk to the study team

Violeta Perez-Rodriguez, Clinical Research Associate  ·  (+44)07871777185  ·  violeta.perez_rodriguez@kcl.ac.uk

Zeryab Meyer, Clinical Research Associate  ·  zeryab.meyer@kcl.ac.uk

Always discuss trial participation with your own doctor first.

Locations (3)

South London and Maudsley NHS Foundation TrustLondon, Greater London, United KingdomRecruiting
Department of Computer Science, Faculty of Engineering Science, University College LondonLondon, Greater London, United KingdomRecruiting
School of Psychology, University of birminghamBirmingham, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06957808